Show simple item record

dc.contributor.authorReagan, Michaela Ruth
dc.contributor.authorSeib, F. Philipp
dc.contributor.authorMcMillin, Douglas William
dc.contributor.authorSage, Elizabeth K.
dc.contributor.authorMitsiades, Constantine S.
dc.contributor.authorJanes, Sam M.
dc.contributor.authorGhobrial, Irene
dc.contributor.authorKaplan, David L.
dc.date.accessioned2013-04-08T20:31:55Z
dc.date.issued2012
dc.identifier.citationReagan, Michaela R., F. Philipp Seib, Douglas W. McMillin, Elizabeth K. Sage, Constantine S. Mitsiades, Sam M. Janes, Irene M. Ghobrial, and David L. Kaplan. 2012. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. Journal of Breast Cancer 15(3): 273-282.en_US
dc.identifier.issn1738-6756en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10512595
dc.description.abstractPurpose Tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, at effective doses remains challenging. Herein we demonstrate the utility of a scaffold-based delivery system for sustained therapeutic cell release that capitalizes on the tumor-homing properties of mesenchymal stem cells (MSCs) and their ability to express genetically-introduced therapeutic genes. Methods: Implants were formed from porous, biocompatible silk scaffolds seeded with full length TRAIL-expressing MSCs (FLT-MSCs). under a doxycycline inducible promoter. In vitro studies with FLT-MSCs demonstrated TRAIL expression and antitumor effects on breast cancer cells. Next, FLT-MSCs were administered to mice using three administration routes (mammary fat pad co-injections, tail vein injections, and subcutaneous implantation on scaffolds). Results: In vitro cell-specific bioluminescent imaging measured tumor cell specific growth in the presence of stromal cells and demonstrated FLT-MSC inhibition of breast cancer growth. FLT-MSC implants successfully decreased bone and lung metastasis, whereas liver metastasis decreased only with tail vein and co-injection administration routes. Average tumor burden was decreased when doxycycline was used to induce TRAIL expression for co-injection and scaffold groups, as compared to controls with no induced TRAIL expression. Conclusion: This implant-based therapeutic delivery system is an effective and completely novel method of anticancer therapy and holds great potential for clinical applications.en_US
dc.language.isoen_USen_US
dc.publisherKorean Breast Cancer Societyen_US
dc.relation.isversionofdoi:10.4048/jbc.2012.15.3.273en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468780/pdf/en_US
dash.licenseLAA
dc.subjectBreast neoplasmsen_US
dc.subjectMesenchymal stem cellsen_US
dc.subjectTissue engineeringen_US
dc.subjectTissue therapyen_US
dc.subjectTNF-related apoptosis-inducing liganden_US
dc.titleStem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalJournal of Breast Canceren_US
dash.depositing.authorMitsiades, Constantine S.
dc.date.available2013-04-08T20:31:55Z
dc.identifier.doi10.4048/jbc.2012.15.3.273*
dash.contributor.affiliatedMcMillin, Douglas
dash.contributor.affiliatedReagan, Michaela Ruth
dash.contributor.affiliatedGhobrial, Irene
dash.contributor.affiliatedMitsiades, Constantine


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record